BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia (2023)
- Authors:
- USP affiliated authors: CASTRO, FABÍOLA ATTIÉ DE - FCFRP ; MENDES, JOAO GUSTAVO PESSINI AMARANTE - ICB
- Unidades: FCFRP; ICB
- DOI: 10.1042/BCJ20210608
- Subjects: IMUNOLOGIA; LEUCEMIA MIELOIDE AGUDA; NEOPLASIAS POR TIPO HISTOLÓGICO; PROTEÍNAS QUINASES
- Agências de fomento:
- Financiametno Cancer Australia and Leukaemia Foundation Australia Priority
- Financiamento CNPq
- Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Processo FAPESP: 2018/25395-1 - Financiamento Australian Cancer Research Foundation
- Financiamento Victorian State Government Operational Infrastructure Support
- Financiamento Australian Government
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Biochemical Journal
- ISSN: 1470-8728
- Volume/Número/Paginação/Ano: v. 480, p. 161–176, 2023
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: hybrid
- Licença: cc-by-nc-nd
-
ABNT
BRUMATTI, Gabriela et al. BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia. Biochemical Journal, v. 480, p. 161–176, 2023Tradução . . Disponível em: https://doi.org/10.1042/BCJ20210608. Acesso em: 27 abr. 2024. -
APA
Brumatti, G., Kaloni, D., Castro, F. A. de, & Amarante-Mendes, J. G. P. (2023). BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia. Biochemical Journal, 480, 161–176. doi:10.1042/BCJ20210608 -
NLM
Brumatti G, Kaloni D, Castro FA de, Amarante-Mendes JGP. BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia [Internet]. Biochemical Journal. 2023 ; 480 161–176.[citado 2024 abr. 27 ] Available from: https://doi.org/10.1042/BCJ20210608 -
Vancouver
Brumatti G, Kaloni D, Castro FA de, Amarante-Mendes JGP. BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia [Internet]. Biochemical Journal. 2023 ; 480 161–176.[citado 2024 abr. 27 ] Available from: https://doi.org/10.1042/BCJ20210608 - Conversion of CD95 (Fas) type II into type I signaling by sub-lethal doses of cycloheximide
- Development and characterization of murine models of T lymphoma to investigate the impact of oncogene expression
- Cosmomycin D, an anthracycline more potent than Doxorubicin for induction of tumor cell death, synergize with imatinib mesilate to induce apoptosis in Bcr-Abl-positive cells
- T lymphoma murine models to study the impact of ectopic expression of anti-apoptotic oncogenes
- Study of pro and anti-apoptotic genes to understand the resistance of apoptosis mediated by Bcr-Abl
- Indoleamine 2,3-dioxygenase expression in chronic myelogenous leukemia patients: association with disease progression
- Apoptotic genes expression in head and neck squamous cell carcinoma (HNSCC) patients
- Expression of pro-apoptotic bid and bik genes is decreased in chronic myeloid leukemia and low levels of bik MRNA are associated with lack of response to imatinib treatment
- BCR–ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients
- Down regulation of Hematopoietic SH2 domain containing (HSH2D) in the progression of the chronic myelogenous leukemia
Informações sobre o DOI: 10.1042/BCJ20210608 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas